GT Biopharma Inc. (GTBP) Targets Multiple Therapies With Breakthrough Pipeline
(GTBP) develops and commercializes innovative immunotherapeutics and has a robust intellectual property portfolio. The $12 billion acquisition of Kite Pharma, Inc. by big-pharma giant, Gilead Sciences earlier this year has biotech investors hungry for the next big buyout target. Does GT Biopharma (GTBP) have what it takes to be a billion dollar opportunity?
Bill Gates Commits To $50M To Battle Alzeheimer’s
Bill Gates is at it again and this time he has his eyes on Alzheimer’s disease with a $50 million dollar investment into the Dementia Discovery Fund based in the U.K. The fund is only two years old and is ran by a VC firm called SV Health and backed by a number of big pharma companies and medical charity Alzheimer’s Research U.K. The firm is focused on supporting groups that conduct R&D on diseases modifying drugs for Alzheimer’s, regardless of years of full of research and limited treatment options.
GET ALERTS FASTER!
TEXT “BIOTECH” TO 474747 NOW!
BIOTECHSTOCKS,.com is owned by MIDAM VENTURES LLC., a Florida Corporation that has been compensated $800,000.00 by a GT Biopharma Inc. for a period beginning August 1, 2017 and ending Nov. 1, 2017 now extended to October 1, 2017 to publicly disseminate information about (GTBP). We own zero shares.